Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort

Research output: Contribution to journalJournal articleResearchpeer-review

  • Ninna Hahn Tougaard
  • Alexandra Louise Møller
  • Pernille Falberg Rønn
  • Tine Willum Hansen
  • Federica Genovese
  • Morten Asser Karsdal
  • Daniel Guldager Kring Rasmussen
  • Rossing, Peter

OBJECTIVE We investigated endotrophin, a profibrotic signaling molecule reflecting collagen VI formation, in serum and urine as risk marker for complications to type 2 diabetes. RESEARCH DESIGN AND METHODS Endotrophin was measured in 774 individuals with type 2 diabetes. Outcomes included a composite kidney end point, first major adverse cardiovascular event (MACE), mortality, progression of albuminuria, incident heart failure, and sight-threatening eye disease. Adjusted Cox proportional hazards models were applied. RESULTS Doubling of serum endotrophin was associated with the kidney end point (n 5 49; hazard ratio 1.80 [95% CI 1.13–2.87]), first MACE (n 5 66; 1.54 [1.04–2.28]), mortality (n 5 156; 1.69 (1.31–2.19]), and incident heart failure (n 5 42; 1.63 [1.02–2.60]). A doubling of urine endotrophin was associated with progression of albuminuria (n 5 85; 1.20 [1.04–1.39]). CONCLUSIONS Serum endotrophin was a risk marker for mortality and kidney and cardiovascular complications in type 2 diabetes. Urine endotrophin was a marker for albu-minuria progression.

Original languageEnglish
JournalDiabetes Care
Volume45
Issue number11
Pages (from-to)2746-2748
Number of pages3
ISSN0149-5992
DOIs
Publication statusPublished - Nov 2022

Bibliographical note

Publisher Copyright:
© 2022 by the American Diabetes Association.

ID: 327067029